Penn Pharmaceutical Services

Penn is a provider of an integrated range of services to the global pharmaceutical industry. They provide consultancy on matters relating to CMC data and the role of the QP. Their core services are Pre-formulation studies, Formulation Development including expertise in poorly soluble molecules, Analytical Services including stability testing, Clinical Trials Supplies from phase I-IV and commercial supply. Penn is a leading provider of Hi Contaiment Solid Oral Dose Manufacturing and for clinical trial manufacturing/packing/labelling/distribution services. Penn has been FDA inspected 9 times in recent years and has 7 QPs on site.

Their product offer and experience is wide - including solid dose forms, liquids, semi solids and high containment processing. Dedicated Phase I and ISS teams

Penn services include:

CMC Consultancy, Formulation Development, Analytical Development, Clinical Trial Supply, Contract Manufacturing, Qualified Persons Release Services, Paediatrics Formulation and Manufacturing, Hi-Potency capabilities, Orphan drug expertise, More than 30 Years of specials, manufacturing expertise, Comparator Sourcing.

The above offerings are all under one roof providing a strong and easy communication channel between departments making developments, manufacturing and analytical processes.

Come and see us at booth #73

Company Type
Mr Michael Kruidenier
Mr Michael Kruidenier

Phynova Group

Phynova is an innovative life sciences company based in Oxford with research facilities in China that uses a plant chemistry platform to develop patented actives for use in pharmaceuticals, nutraceuticals, and personal care products. Drug candidates and functional ingredients under development target post-operative ileus (POI), MRSA, hepatitis C, glucose control and hyperpigmentation and melanin production.

Come and see us at booth #73

Company Type
Dr Ian Scoular


Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical trials, reducing the need for animal experiments. This optimisation also improves the efficacy of combinations in pre-clinical xenografts.

The company is also developing:

(i) Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials.

(ii) Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates early on in the drug discovery process.

(iii) Drug combinations database, for researchers and clinicians to rapidly access literature data on pre-clinical and clinical regimens and their effects.

Physiomics has worked with Eli Lilly since 2007 and recently added a further two large pharmaceutical clients. In addition, Physiomics has collaborated with a number of other companies including Bayer Technology Services, Sareum, ValiRx, Cancer Research Technologies and Cyclacel. Fee-for-service, licensing and revenue sharing options are available.

Company Type
Mr Mark Chadwick


ProImmune is your ideal strategic partner for managing the immunogenicity risk of biological drugs, the discovery of new antigens, e.g. for targeted sub-unit vaccines, and monitoring immune responses, such as cellular and humoral immune responses, with the most advanced technologies.

Whether you are looking to improve the specificity of your therapy, reduce unwanted immunogenicity or simply broaden your IP portfolio, we can provide all or any part of the solution.

Come and see us at booth #73

Company Type
Mr Matthew Frayne

Q-Chip United Kingdom

Q Chip is using a novel approach to encapsulate therapeutics in bioresorbable polymer microspheres for injection and sustained drug release (SR). We avoid the use of harsh solvents, high temperatures and shearing forces and achieve a tuneable output with high API loading and microsphere monodispersity, minimising production cost and controlling burst release.

We have demonstrated successful sustained release for peptide GnRH and SST agonists; the technology is also applicable for small and insoluble molecules. Through partnerships/collaborations, we are now exemplifying our platform in a range of therapeutic areas, both for NCEs and generics.

Q Chip's Dutch site (Q Chip BV) opened in 2011; this new facility will be used for the GMP manufacture of clinical trial material.

Q Chip's technology platform Q-Sphera is based on the use of benign encapsulation and desolvation conditions to create highly monodisperse microspheres of bioresorbable polymer containing drug. The technology lends itself to the rapid development of novel SR formulations, the encapsulation of conventional NCEs (small molecules, peptides) as well as life cycle management and generics development.

Company Type
Dr Cora Griffin


Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.

Come and see us at booth #73

Company Type
Dr Tim Mitchell

SCM Pharma United Kingdom

SCM Pharma is a UK-based contract pharmaceutical organisation (CMO) that works with clients progressing drugs through clinical trials and others that require ongoing small-medium scale commercial supply of licensed products.

With expertise in novel, difficult and dangerous products and medical devices requiring complex fill/finish, the specialist CMO provides a wide range of sterile and non-sterile development, manufacturing and packaging services to meet client needs. These services include terminal sterilisation, aseptic processing (including biologicals and radio-labelled molecules) and handling highly potent products including cytotoxics and cytostatic.

Come and see us at booth #73

Company Type
Ms Joanne Anderson
Business Development Manager 


Selcia Limited is a leading worldwide provider of contract research services. Our headquarters are in Ongar, Essex and we have a branch in Hopkinton, MA. Selcia operates two divisions, Selcia Discovery, which provides integrated small molecule drug discovery to pharmaceutical and biotech clients, and Selcia Radiolabeling which specializes in 14C GMP radiolabelling.

In addition to general medicinal chemistry and biology capabilities applicable across a range of target classes, Selcia Discovery has particular strengths in three unique and highly synergistic technologies:
(1) medicinal chemistry of complex natural products
(2) capillary electrophoresis-based fragment and natural product screening
(3) PPI targets in particular peptidyl-prolyl isomerase targets (including cyclophilins, FKBPs, Pin1, together called PPIases).
Whilst relatively neglected by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural product derivatives or have structures inspired by natural products.

The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to clients, but has also generated IP for Selcia, which we have recently demerged into a new company, Mitopharm Limited who are in advanced license negotiations for a breakthrough drug in the field of acute and chronic neurodegenerative diseases. Other applications in the fields of chronic inflammatory diseases, oncology, COPD, and virus infections will be developed by Mitopharm either via investment or via joint R&D programs with pharmaceutical companies.

We have also recently established Selcia Pharma, a spin out company focussed on the optimisation/preclinical development and partnering of Selcia’s preclinical antimicrobial (antibacterial & antifungal) assets.

Come and see us at booth #73

Company Type
Mr Dave Roberts
Mr Simon Bury

Sera Laboratories International

Seralab is a leading supplier of biological material to Life Science.

The company offers the most complete range of human and animal-based bioproducts in Europe. Seralab supplies serum, plasma, whole blood, tissues, tissue homogenates,hepatocytes, microsomes, S9 fractions and fluids from the human model and an extensive range of animal species.

Human disease state material includes serum, plasma, whole blood, CSF and other tissue and fluid samples from donors with a wide range of diseases including autoimmune disease and cancer states.
Pre-clinical Research tools are also available from healthy, treated or diseased animals, in the form of cells, fluids or tissues, from a wide range of validated animal models of human inflammatory diseases used by Pharmaceutical companies , for example Asthma, Alzheimer’s and Rheumatoid Arthritis.

Other products include Cell Culture sera and reagents including Foetal Bovine Serum, Cell Specific media selected growth factors and Stem Cell reagents.

Our UK Production company APS Ltd offers a range of Custom Services, including Sterile Filtration and bottling, Buffer Production, Monoclonal and Polyclonal Antibody Production, Kit Manufacture and many other services, tailored to meet your outsourcing requirements.

Seralab is looking to introduce the company and products/service to a wider audience and to investigate possibilities for collaboration.

Company Type


Vivacta is developing a unique monitoring system to measure patient outcomes in real time at the point-of-care, whether in the hospital, in physician offices or at home. For chronic therapies, regular near-patient monitoring of drug levels and drug response allows faster therapy adjustment and longer periods within therapeutic range, leading to improved clinical and economic outcomes of interest to reimbursement agencies. The system, which uses revolutionary piezofilm technology but which requires no sample preparation, puts the precision and performance of lab-based analysers at the disposal of non-expert users including patients themselves. In a world where clinical and economic outcomes increasingly drive reimbursement of new therapies and affect re-appraisal of established treatments, the simple-to-use Vivacta desktop device has the potential to revolutionise the personalisation of pharmaceutical care.

Vivacta is a privately-held, venture capital-backed medical diagnostic company developing its proprietary piezofilm technology to achieve extremely high sensitivity and dynamic range for a new generation of diagnostic and monitoring products adapted to near-patient testing. The company's system has been validated for large molecules such as proteins as well as small molecule drugs and provides actionable information to users in 5-10 minutes. Beyond diagnosis of disease, the platform has significant utility in the monitoring of drug levels simultaneously with the monitoring of drug response (measuring biomarkers of drug response, disease response or other pharmacodynamic measures, including anti-drug antibodies or other prognostic measures). While the system also has the potential to measure nucleic acid analytes, useful in the pharmacogenomic prediction of patient response to therapy, the system’s broader applications in personalised medicine arise from its capacity to measure protein and small molecule analytes, rapidly and locally.

come see us at booth #73

Company Type
Mr Oliver Bouchet